Andrea Ardizzoni

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/ <i>neu</i> –Positive Metastatic Breast Cancer

Antonino Musolino, Nadia Naldi, Beatrice Bortesi et al. · Journal of Clinical Oncology · 2008 · 949 citations · Full text

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Anne‐Marie C. Dingemans, Martin Früh, Andrea Ardizzoni et al. · Annals of Oncology · 2021 · 530 citations · Full text

Medicine, Cancer Management, Bronchial Neoplasm +7

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

Andrea Ardizzoni, H. Hansen, P Dombernowsky et al. · Journal of Clinical Oncology · 1997 · 479 citations

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Jean‐Charles Soria, Enriqueta Felip, Manuel Cobo et al. · The Lancet Oncology · 2015 · 429 citations

Second-line Treatment, Afatinib Versus Erlotinib, Medicine +7